You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 再鼎醫藥升超5% FDA加速批准新癌症免疫療法
格隆匯3月29日丨再鼎醫藥(9688.HK)升超5%,報26.7港元,總市值261億港元。Incyte公司宣佈,美國FDA加速批准人源化抗PD-1單克隆抗體Zynyz(retifanlimab)上市,用於治療轉移性或復發局部晚期默克爾細胞癌(MCC)成人患者。這一適應症的加速批准是基於患者的緩解率和緩解持續時間(DOR)。MCC是一種侵襲性強的皮膚癌,通常進展迅速,出現轉移性疾病風險高,導致預後不良。出現遠端轉移瘤的患者的估計5年生存率為14%。Zynyz是一款靜脈注射的PD-1抑制劑,它通過與PD-1受體結合,抑制PD-1介導的對免疫細胞活性的抑制,提高免疫細胞發現和殺傷腫瘤細胞的能力。2019年7月,再鼎醫藥與Incyte公司達成研發協議,獲得retifanlimab在大中華區在血液和實體腫瘤領域的獨家開發權益。目前,retifanlimab還在臨牀試驗中用於治療非小細胞肺癌、肛管鱗狀細胞癌等其它癌症類型。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account